Praxsyn executes new services agreement with NHS Pharma
Through its relationship with NHS, Mesa’s revenue has grown significantly over the past six months. NHS is building on its mutually beneficial relationship and taking on a more
Through its relationship with NHS, Mesa’s revenue has grown significantly over the past six months. NHS is building on its mutually beneficial relationship and taking on a more
AVA-101 also showed an improvement on best corrected visual acuity (BCVA) compared with the control group and a positive trend in response rate (stable vision with few rescue
Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy
The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.
The Hungarian Nobel-prize winning scientist Albert Szent-Györgyi envisioned cancer cures that go beyond large molecules including genes and proteins, but rather target sub-molecular mechanisms, where the electrons play
As recently reported at the American Society of Clinical Oncology (ASCO) annual meeting, results show a significant reduction in the Total Symptom Score (TSS) (the proportion of patients
The study, entitled "Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion" authored by Andreas Müssigbrodt et
The grant will help fund an examination of the interaction of over 1400 FDA-Approved drugs and drug-like compounds with a variety of bromodomains, and facilitate the creation of
This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was
Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. A copy of the poster, entitled "Updated